Tag: Cantor Fitzgerald
-
Why CRISPR is Becoming a Standout Winner
CRISPR Therapeutics could be a standout winner this year, we said on April 13. We also noted, “Cantor Fitzgerald initiated coverage with an outperform rating, with a $72 price target, with the firm expecting CRSP to get a nod for its gene-editing therapy, exa-cel.” At the time, CRSP traded around $44. Today, it’s up to…
-
CRISPR Therapeutics Could be a Standout Winner this Year
Gene editing stocks, like CRISPR Therapeutics (CRSP), are on the. move. In fact, CRSP is up about 15% on the day on a volume spike to 2.6 million shares, as compared to daily average volume of 1.04 million. All after analysts at Cantor Fitzgerald initiated coverage with an outperform rating, with a $72 price target. …
-
Pay Close Attention to Anavex Life Sciences
Keep an eye on Anavex Life Sciences (AVXL). Over the last few months, the stock exploded from a low of about $4 to 30. While the stock recently pulled back, use the weakness as opportunity. All after reporting that the “predictive biomarker of response established with SIGMAR1 mRNA expression correlates significantly with responses in primary…
-
This is Why Cassava Sciences (SAVA) Could Explode — Again
Cassava Sciences (SAVA) is soaring again. After pulling back to strong support around $91, the stock is back to $108 thanks to new price targets, and progress on its lead drug candidate for Alzheimer’s. H.C. Wainwright raised its price target to $124 on SAVA. Cantor Fitzgerald raised its target to $100. Better, the company already…